These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29253204)

  • 1. In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.
    Spec A; Connolly P; Montejano R; Wheat LJ
    Med Mycol; 2018 Oct; 56(7):834-837. PubMed ID: 29253204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.
    Wheat LJ; Connolly P; Smedema M; Durkin M; Brizendine E; Mann P; Patel R; McNicholas PM; Goldman M
    J Antimicrob Chemother; 2006 Jun; 57(6):1235-9. PubMed ID: 16627592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
    Hazirolan G; Canton E; Sahin S; Arikan-Akdagli S
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4841-7. PubMed ID: 23877683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
    Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
    Buil JB; Brüggemann RJM; Wasmann RE; Zoll J; Meis JF; Melchers WJG; Mouton JW; Verweij PE
    J Antimicrob Chemother; 2018 Jan; 73(1):134-142. PubMed ID: 29048485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.
    Wheat LJ; Connolly P; Smedema M; Brizendine E; Hafner R;
    Clin Infect Dis; 2001 Dec; 33(11):1910-3. PubMed ID: 11692303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
    Brilhante RSN; Guedes GMM; Silva MLQD; Castelo-Branco DSCM; Cordeiro RA; Sidrim JJC; Rocha MFG
    Int J Antimicrob Agents; 2018 Aug; 52(2):272-277. PubMed ID: 29592837
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
    Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
    Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
    González GM
    Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
    Guinea J; Recio S; Escribano P; Peláez T; Gama B; Bouza E
    Antimicrob Agents Chemother; 2010 Sep; 54(9):4012-5. PubMed ID: 20566770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
    Astvad KMT; Hare RK; Arendrup MC
    Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.
    Najafzadeh MJ; Saradeghi Keisari M; Vicente VA; Feng P; Shamsian SA; Rezaei-Matehkolaei A; de Hoog GS; Curfs-Breuker I; Meis JF
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6395-8. PubMed ID: 24100491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of fluconazole-susceptible and -resistant isolates of Malassezia pachydermatis against azoles.
    Jesus FP; Lautert C; Zanette RA; Mahl DL; Azevedo MI; Machado ML; Dutra V; Botton SA; Alves SH; Santurio JM
    Vet Microbiol; 2011 Aug; 152(1-2):161-4. PubMed ID: 21658868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
    Badali H; Khodavaisy S; Fakhim H; de Hoog GS; Meis JF; Chowdhary A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7818-22. PubMed ID: 26369976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
    Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
    J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.